Financing ·
Lyell Immunopharma raises $80.0 million in private placement and reports Q3 net loss of $45.5 million
LYELLyell Immunopharma, Inc.
Lyell Immunopharma announced an $80.0 million private placement with existing and new investors to extend its cash runway into 2028, bringing total liquidity to approximately $194.0 million as of September 30, 2026. The company also reported financial results for the third quarter ended September 30, 2026, posting a net loss of $45.5 million compared to $38.8 million in the prior-year period, driven by a $12.7 million increase in research and development expenses from heightened clinical trial activity. Additionally, Lyell highlighted updated clinical data for its ronde-cel program from the PiNACLE pivotal trial and completed technology transfer of LYL273 to its manufacturing center. The company operates as a late-stage clinical biotechnology firm advancing next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.